STK31 and cancer: The BGS data revealed that 8 of the 10 CC patients exhibited nearly complete hypermethylation STK31 prior to neoadjuvant chemotherapy and exhibited no methylation changes after chemotherapy (T1-T4 are shown as examples of the cancer patients exhibited nearly complete hypermethylation STK31 prior to neoadjuvant chemotherapy and exhibited no methylation changes after chemotherapy), and 2 cases (T5-T6) of the 10 CC samples had statuses of hypomethylation prior to neoadjuvant chemotherapy and exhibited hypermethylation after chemotherapy (Additional file 3: Figure S3A-1).